T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company's Candida auris test. The Company recently announced plans to add C. auris detection to its FDA-cleared T2Candida Panel.
jizzudin fizzydrink : what’s the date for the FDA approvals
Biff OP jizzudin fizzydrink : No one knows but the FDA